Moxifloxacin May Be Better for COPD Outpatients According to New Research Published in the International Journal of COPD
Posted Jan 21 2010 10:23am
Chronic obstructive pulmonary disease (COPD) affects a large number of subjects worldwide and is characterised by a progressively rising epidemiological, clinical and socio-economic impact. The objectives of treatment are to decrease the burden of the disease through relief of symptoms, improvement of exercise tolerance, and prevention and treatment of exacerbations.
Original research to investigate the long-term impact on health related quality of life (HRQL) of the antibiotic treatment of exacerbations of COPD in general practice, has been released in a new research paper, available from Dove Medical Press.
The investigation, comparing the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for five days) and amoxicillin/clavulanate (500/125 mg three times a day for 10 days) on HRQL, is authored by Marc Miravitlles, Carles Llor, Jesús Molina, et al on behalf of the EVOCA Study Group, in Barcelona, Spain.
The EVOCA study was a prospective, observational, multi-centre study of a cohort of patients with COPD followed in primary care over a two-year period.